Lassen Therapeutics reels in $85M Series B for PhII testing in thyroid eye disease

Lassen Therapeutics closed an oversubscribed $85 million Series B on Tuesday morning as the San Diego biotech brings its treatment candidate for thyroid eye disease into Phase II testing.

The Frazier Life Sciences-founded startup is attempting to go into a field with multiple other biotechs in clinical development, but Lassen…
Click here to view original post